Sun Pharmaceutical Industries DuPont analysis

Profitability Growth Credit Liquidity Working capital Dividend yield DuPont CAGR

Per cent unless marked ×

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

5-step DuPont — ROE = tax burden × interest burden × EBIT margin × turnover × leverage						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	0.76×	0.76×	0.80×	0.87×	0.90×
	1.08×	1.02×	1.08×	1.06×	1.03×
	24.8%	25.3%	24.1%	21.6%	20.8%
	0.58×	0.58×	0.59×	0.58×	0.58×
	1.30×	1.30×	1.27×	1.27×	1.36×
	15.2%	14.8%	15.6%	14.6%	15.3%
	14.7%	14.7%	16.1%	16.0%	16.3%

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SUNPHARMA₹1,761.00

Sun Pharmaceutical Industries Ltd.

· Pharma & Health

₹ CrorePeersCIPLA DRREDDY LUPIN APOLLOHOSP MAXHEALTH DIVISLAB TORNTPHARM ZYDUSLIFEMcap ₹4.23L Cr

Profitability Growth Credit Liquidity Working Capital Yield Analysis DuPont

Ratios — % unless marked × 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
5-Step DuPont — ROE = Tax Burden × Interest Burden × EBIT Margin × Turnover × Leverage
Tax Burden (Net Income/Pretax) ×	0.90	0.87	0.80	0.76	0.76
Interest Burden (Pretax/EBIT) ×	1.03	1.06	1.08	1.02	1.08
EBIT Margin %	20.78	21.58	24.15	25.30	24.82
Asset Turnover ×	0.58	0.58	0.59	0.58	0.58
Financial Leverage (Assets/Equity) ×	1.36	1.27	1.27	1.30	1.30
ROE (5-step product, year-end total equity) %	15.32	14.64	15.63	14.81	15.21
ROE (owners' profit / average owners' equity) %	16.29	16.01	16.09	14.74	14.74

No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 199%.